UroGen Pharma Reports Q2 2025 Results and Launches ZUSDURI

Urogen Pharma ( (URGN) ) has released its Q2 earnings. Here is a breakdown of the information Urogen Pharma presented to its investors.

UroGen Pharma Ltd., a biotechnology company, focuses on developing and commercializing innovative treatments for urothelial and specialty cancers, utilizing its proprietary RTGel technology for sustained drug delivery.

In its second quarter of 2025, UroGen Pharma announced the launch of ZUSDURI™, the first FDA-approved treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, marking a significant milestone for the company. Additionally, the company reported a year-over-year growth in net product sales for JELMYTO®, another key product in its portfolio.

Key financial highlights include JELMYTO achieving net product sales of $24.2 million, reflecting an 11% increase from the previous year, driven by a 7% growth in demand and favorable pricing. The company also reported a net loss of $49.9 million, attributed to increased research and development expenses and commercial preparation costs for ZUSDURI. UroGen’s cash and equivalents stood at $161.6 million as of June 30, 2025.

Strategically, UroGen is advancing its pipeline with the completion of enrollment in the Phase 3 UTOPIA trial for UGN-103 and the initiation of a Phase 3 study for UGN-104. The company is also exploring next-generation mitomycin formulations and immuno-oncology candidates, positioning itself for sustained growth and innovation.

Looking ahead, UroGen remains optimistic about its market opportunities, particularly with ZUSDURI’s launch, and is committed to advancing its strategic initiatives to drive growth while maintaining a strong financial position.